The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Following a +7.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where CING advanced for three days, in 193 of 228 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
The 10-day RSI Indicator for CING moved out of overbought territory on October 28, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 similar instances where the indicator moved out of overbought territory. In 18 of the 21 cases, the stock moved lower in the following days. This puts the odds of a move lower at 86%.
The Momentum Indicator moved below the 0 level on November 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CING as a result. In 71 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The Moving Average Convergence Divergence Histogram (MACD) for CING turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 39 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.
CING moved below its 50-day moving average on November 03, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CING crossed bearishly below the 50-day moving average on November 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CING declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
CING broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CING entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. CING’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.640) is normal, around the industry mean (3.498). P/E Ratio (-1.197) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CING’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where CTMX advanced for three days, in 182 of 235 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CTMX's RSI Indicator exited the oversold zone, 33 of 44 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
CTMX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CTMX as a result. In 76 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The Moving Average Convergence Divergence Histogram (MACD) for CTMX turned negative on November 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 36 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CTMX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for CTMX entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Seasonality Score of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.580) is normal, around the industry mean (3.498). P/E Ratio (-3.842) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (27.624) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. CTMX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CTMX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
CTMX | ||
|---|---|---|
OUTLOOK RATING 1..100 | 4 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 27 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 97 | |
PRICE GROWTH RATING 1..100 | 85 | |
P/E GROWTH RATING 1..100 | 98 | |
SEASONALITY SCORE 1..100 | 10 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| CING | CTMX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 86% | 2 days ago 75% |
| Stochastic ODDS (%) | 2 days ago 88% | 2 days ago 74% |
| Momentum ODDS (%) | 2 days ago 83% | 2 days ago 87% |
| MACD ODDS (%) | 2 days ago 81% | 2 days ago 84% |
| TrendWeek ODDS (%) | 2 days ago 88% | 2 days ago 86% |
| TrendMonth ODDS (%) | 2 days ago 88% | 2 days ago 87% |
| Advances ODDS (%) | 2 days ago 85% | 15 days ago 77% |
| Declines ODDS (%) | 7 days ago 90% | 9 days ago 88% |
| BollingerBands ODDS (%) | 2 days ago 84% | 2 days ago 76% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 84% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CING’s FA Score shows that 0 FA rating(s) are green while CTMX’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CING’s TA Score shows that 2 TA indicator(s) are bullish while CTMX’s TA Score has 4 bullish TA indicator(s).
CING (@Biotechnology) experienced а -3.39% price change this week, while CTMX (@Biotechnology) price change was -9.17% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
CING is expected to report earnings on Nov 12, 2026.
CTMX is expected to report earnings on Feb 24, 2027.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, CTMX has been loosely correlated with MLEC. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if CTMX jumps, then MLEC could also see price increases.
| Ticker / NAME | Correlation To CTMX | 1D Price Change % | ||
|---|---|---|---|---|
| CTMX | 100% | N/A | ||
| MLEC - CTMX | 42% Loosely correlated | N/A | ||
| VKTX - CTMX | 41% Loosely correlated | -1.14% | ||
| IMTX - CTMX | 40% Loosely correlated | -0.16% | ||
| EDIT - CTMX | 40% Loosely correlated | -8.91% | ||
| AURA - CTMX | 38% Loosely correlated | -0.13% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| PBPH | 31.64 | -0.05 | -0.16% |
| Portfolio Building Block World Pharma and Biotech Index ETF (PBPH) | |||
| EMBX | 49.49 | -0.21 | -0.42% |
| VanEck Emerging Markets Bond ETF (EMBX) | |||
| ENHI | 26.67 | -0.16 | -0.60% |
| iShares Enhanced International Active ETF (ENHI) | |||
| PCLG | 22.06 | -0.22 | -1.01% |
| Polen Focus Growth ETF (PCLG) | |||
| TSEG | 2.59 | -0.14 | -5.13% |
| Leverage Shares 2X Long TSEM Daily ETF (TSEG) | |||